STAT+: Here’s how Insmed grows to be the next $100 billion biotech
Insmed's CEO keeps a newspaper story from 2014 in his office. The headline: “Insmed joins the biotech trash heap.” Now, he hopes the company can be a $100 billion biotech.
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
Insmed CEO Will Lewis keeps a newspaper story from 2014 framed on the wall of his office. The headline reads, “Insmed joins the biotech trash heap.”
If you’re wondering, I didn’t write that story, although I could have. It wasn’t hard to find Insmed skeptics back when the company was struggling to develop the lung-infection drug now known as Arikayce.
